Clinical trials: Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in…
- Trial name
- CHAMPION-01 (NCT07663253)
- Testing
- Isatuximab, Bortezomib, Lenalidomide
- Where
- 13 sites in China
- Volunteers
- 333 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma, Frailty
Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
Frailty is dynamic and confers poor outcomes in elderly patients with newly diagnosed multiple myeloma (NDMM), mainly because of the high prevalence of treatment discontinuation due to intolerability.
- Trial name
- DynaFiT (NCT06099912)
- Where
- China
- Volunteers
- 131 people
- Sponsor
- FengYan Jin
Newly Diagnosed Multiple Myeloma
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
Multiple myeloma (MM) is a malignant disease of the BM characterized by clonal expansion of plasma cells. Current guidelines recommend that newly diagnosed transplant-eligible patients with multiple myeloma (NDMMTE) shall undergo…
- Trial name
- ELIAS (NCT05665140)
- Testing
- Isatuximab, Lenalidomide, Bortezomib
- Where
- 6 sites in Germany
- Volunteers
- 100 people
- Sponsor
- University Hopsital Schleswig Holstein Campus Lübeck
Myeloma Multiple
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with…
- Trial name
- NCT07085728
- Testing
- Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis.
- Trial name
- NCT00089167
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Plasma Cell Myeloma
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant
This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant.
- Trial name
- NCT02880228
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
- Conditions
- Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
- Trial name
- NCT04653246
- Testing
- Isatuximab, Lenalidomide, Bortezomib Injection
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jacob Laubach, MD
Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others.
- Trial name
- iFIT (NCT07649525)
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,226 people
- Sponsor
- University of Leeds
Multiple Myeloma
Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
This study aims to evaluate the overall response rate after 4 cycles and the best response to induction therapy with combination of lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed…
- Trial name
- NCT02219178
- Testing
- lenalidomide, Subcutaneous bortezomib, Dexamethasone
- Where
- 8 sites in Ireland
- Volunteers
- 42 people
- Sponsor
- Cancer Trials Ireland
Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
This pilot phase I clinical trial studies how well copper 64Cu-DOTA-daratumumab positron emission tomography works in diagnosing patients with multiple myeloma that has come back.
- Conditions
- Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
- Trial name
- NCT03311828
- Testing
- Daratumumab, Imaging Agent, Positron Emission Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed patients with multiple myeloma that…
- Trial name
- NCT04258683
- Testing
- Pembrolizumab
- Where
- 4 sites in Canada
- Sponsor
- Canadian Myeloma Research Group
Myeloma
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
Phase I/II trial of Carfilzomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma. Nine: University Hospital of Nantes, University Hospital of Nancy, University Hospital of Lille, University…
- Trial name
- CARMYSAP (NCT01279694)
- Testing
- Carfilzomib, Melphalan, Prednisone
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
The purpose of Phase 1b of the study is to determine the maximum tolerated dose (MTD) of oprozomib in combination with melphalan and prednisone (OMP).
- Trial name
- NCT02072863
- Testing
- Oprozomib, Melphalan, Prednisone
- Where
- 8 sites in Greece, Italy and 1 more
- Volunteers
- 9 people
- Sponsor
- Amgen
Multiple Myeloma
Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Complete Response (CR) plus near CR rate of VAD (Vincristine, Adriamycin, Dexamethasone) induction chemotherapy followed by ASCT in patients with newly diagnosed MM was about 50% and CR plus near CR rate of PAD (Bortezomib…
- Trial name
- NCT01255514
- Testing
- high dose dexamethsone
- Where
- 8 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Yonsei University
Multiple Myeloma
Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Due to economic reasons, thalidomide is still widely used as a first line drug for Multiple Myeloma patients in China. However,the efficacy of CTd is still lower than the therapeutic regimens with new drugs.
- Trial name
- CTd (NCT02248428)
- Testing
- Clarithromycin, Thalidomide, Cyclophosphamide
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Jinling Hospital, China
Multiple Myeloma
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Bortezomib-based triple-drug combination has greatly improved the response rate of multiple myeloma patients. Bortezomib,doxorubicin,and dexamethasone (PAD) is commonly used in clinical practice.Recent studies have found that…
- Trial name
- NCT02362165
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
The primary objective of this observational study is to identify the molecular profiles and clinical characteristics that define subsets of myeloma patients during the course of the disease.
- Trial name
- CoMMpass (NCT01454297)
- Where
- 73 sites in United States, Canada and 1 more
- Volunteers
- 1,154 people
- Sponsor
- Multiple Myeloma Research Foundation
Multiple Myeloma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with…
- Trial name
- LINKER-MM4 (NCT05828511)
- Testing
- Linvoseltamab
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Hematologic Diseases
Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to compare clinical judgment and comprehensive geriatric assessment as screening tools for optimization of treatment for newly diagnosed elderly multiple myeloma patients.
- Trial name
- COMPASS (NCT02918695)
- Where
- 20 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hematological Patients, Newly Diagnosed Multiple Myeloma
Biomarkers in Multiple Myeloma
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in…
- Conditions
- Hematological Patients, Newly Diagnosed Multiple Myeloma, Chemotherapy
- Trial name
- VESICOM (NCT05259553)
- Testing
- Blood samples
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne